长沙晚报掌上长沙12月30日讯 截至12月30日收盘：沪指涨-0%，报3965.1159点；深证成指涨0.49%，报 13604.067点。 湘股12月30日涨幅TOP5 *ST张股开盘价7.570，收盘报7.570元，当日涨4.99%，当日最高价为7.570元，最低价为7.570元，成交量 0.0468万手。 *ST高斯开盘价8.230，收盘报8.550元，当日涨4.14%，当日最高价为8.620元，最低价为8.190元，成交量 10.2682万手。 梦洁股份开盘价3.910，收盘报4.030元，当日涨2.81%，当日最高价为4.220元，最低价为3.880元，成交量 42.9632万手。 科力尔开盘价13.390，收盘报13.610元，当日涨2.48%，当日最高价为13.730元，最低价为13.290元，成交 量25.5022万手。 长缆科技开盘价18.310，收盘报18.890元，当日涨1.94%，当日最高价为19.100元，最低价为18.010元，成 交量11.2607万手。 湘股12月30日跌幅TOP5 博云新材开盘价12.050，收盘报11.720元，当日跌-4.95%，当日最高价为12.280元 ...

格隆汇12月25日丨*ST四环(000518.SZ)在投资者互动平台表示，公司的苗木销售业务一年四季皆有，其 中春秋属于销售旺季。 ...

证券之星消息，12月25日生物制品板块较上一交易日上涨0.18%，金迪克领涨。当日上证指数报收于 3959.62，上涨0.47%。深证成指报收于13531.41，上涨0.33%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688670 | 金克 | 22.45 | 4.66% | 6.68万 | 1.48亿 | | 688443 | 智翔金泰 | 27.07 | 3.08% | 3.78万 | 1.01亿 | | 000518 | *ST四环 | 2.46 | 2.93% | 10.92万 | 2642.85万 | | 000534 | 万泽股份 | 24.15 | 2.33% | 20.35万 | 4.88亿 | | 688520 | 神州细胞 | 44.55 | 1.71% | 2.72万 | 261T | | 301080 | 百普賽斯 | 55.23 | 1.56% | 1.40万 | 7720.60万 | | 002773 | 康弘药业 | 31.17 ...

（文章来源：证券时报网） | 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 年线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 603305 | 旭升集 | 10.01 | 8.74 | 14.21 | 15.38 | 8.27 | | | 团 | | | | | | | 600279 | 重庆港 | 10.02 | 2.26 | 5.38 | 5.82 | 8.15 | | 002253 | *ST智胜 | 4.98 | 3.86 | 11.05 | 11.60 | 4.95 | | 920098 | 科隆新 材 | 6.73 | 8.81 | 31.60 | 33.00 | 4.42 | | 603809 | 豪能股 份 | 10.02 | 10.15 | 13.46 | 14.05 | 4.39 | | 600860 | 京城股 份 | 6.07 | 4.16 | 12.07 | 12.59 | 4.32 | | 600892 | *ST大晟 ...

Core Viewpoint - The market experienced mixed performance with the ChiNext index closing down 0.44%, while the influenza and organic silicon sectors surged, indicating a divergence in market sentiment driven by specific sectoral developments [1][4]. Group 1: Influenza Sector - The influenza sector saw a significant uptick, with flu-like cases in northern provinces rising to 7.0%, markedly higher than the same period in previous years [4]. - Sales of antiviral drugs, such as Oseltamivir, surged by 237% over the past week, indicating strong demand driven by rising flu cases [4]. - Jindike has completed the production season with 1.56 million doses of its quadrivalent flu vaccine approved for release, and is ramping up production capacity to 30 million doses [4]. Group 2: Organic Silicon Sector - The organic silicon sector experienced a boost following Dow Chemical's announcement of a 10%-20% price increase on major products starting December 10, which acted as a catalyst for domestic stocks [4]. - Companies like Hongbai New Materials and Chenguang New Materials saw their stocks hit the daily limit, while Dongyue Silicon Material rose over 10% [4]. - Smart money has already positioned itself in this sector, with Chenguang New Materials seeing a net inflow of 85.14 million yuan over the past ten trading days [4]. Group 3: Underperforming Sectors - The Hainan sector faced significant declines, with companies like Jingliang Holdings and Hainan Haiyao dropping nearly 7%, highlighting the lack of performance support for regional themes [4]. - The film and content industry also struggled, with Huanrui Century hitting the daily limit down and Shanghai Film falling nearly 7%, reflecting uncertainty in the content sector [4]. Group 4: Market Sentiment and Strategy - The overall trading volume decreased by 93.5 billion yuan compared to the previous day, indicating a cautious market sentiment and a tendency for rapid sector rotation [4]. - Investment strategies suggest focusing on the influenza sector for low-entry opportunities and the organic silicon sector for potential gains, while avoiding sectors lacking performance, policy support, or growth potential [5].

Core Insights - The biopharmaceutical sector experienced a decline of 0.98% on November 18, with He Yuan Bio leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance Summary - Notable gainers included: - Aopu Mai (688293) with a closing price of 58.80, up 3.38% on a trading volume of 15,900 shares and a transaction value of 93.39 million [1] - Jin Hu Ke (688670) at 26.80, up 2.88% with a volume of 116,300 shares and a transaction value of 319 million [1] - Te Bao Bio (688278) at 77.08, up 1.22% with a volume of 10,800 shares and a transaction value of 82.57 million [1] - Notable decliners included: - Bu Yuan Bio (688765) at 79.95, down 3.89% with a volume of 56,800 shares and a transaction value of 458 million [2] - San Sheng Guo Jian (688336) at 67.60, down 3.87% with a volume of 68,100 shares and a transaction value of 469 million [2] - Wo Wu Bio (300357) at 31.77, down 3.23% with a volume of 77,900 shares and a transaction value of 250 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 981 million from institutional investors, while retail investors contributed a net inflow of 819 million [2] - Key stocks with significant capital flow included: - Hua Lan Vaccine (301207) with a net inflow of 48.51 million from institutional investors [3] - Rong Chang Bio (688331) with a net inflow of 23.62 million from institutional investors [3] - Jin Ke (688670) with a net inflow of 5.53 million from institutional investors [3]

Market Overview - The biopharmaceutical sector experienced a slight decline of 0.08% on November 11, with He Yuan Bio leading the drop [1] - The Shanghai Composite Index closed at 4002.76, down 0.39%, while the Shenzhen Component Index closed at 13289.0, down 1.03% [1] Stock Performance - Notable gainers included: - Jin Ke (688670) with a closing price of 24.97, up 19.99% on a trading volume of 134,300 shares and a transaction value of 310 million [1] - Kanghua Bio (300841) closed at 83.21, up 6.04% with a trading volume of 57,100 shares [1] - Watson Bio (300142) closed at 12.82, up 2.64% with a trading volume of 942,000 shares [1] - Significant losers included: - Bu Yuan Bio (688765) closed at 86.00, down 8.02% with a trading volume of 107,600 shares [2] - Ao Pu Mai (688293) closed at 59.18, down 3.65% with a trading volume of 17,900 shares [2] - Rongchang Bio (688331) closed at 86.00, down 2.55% with a trading volume of 45,900 shares [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 671 million from institutional investors, while retail investors contributed a net inflow of 335 million [2] - The capital flow for key stocks showed: - Jin Ke had a net inflow of 48.11 million from institutional investors, but a net outflow of 24.49 million from speculative funds [3] - Zhifei Bio (300122) experienced a net inflow of 15.25 million from institutional investors, with a net outflow of 23.20 million from retail investors [3] - Kanghua Bio had a net inflow of 14.35 million from institutional investors, but a net outflow of 23.26 million from speculative funds [3]

Group 1 - The core point of the article is that *ST SiHuan has undergone a significant change in its ownership structure, with Bihui Agricultural Investment acquiring a controlling stake in the company through a judicial auction [1] - Bihui Agricultural Investment has acquired 28,599 million shares, which represents 27.78% of the total share capital of *ST SiHuan [1] - The transaction was completed at a price of 388 million yuan, and the transfer of shares was finalized in January 2025 [1] Group 2 - Following the acquisition, Bihui Agricultural Investment has become the controlling shareholder of *ST SiHuan [1] - Qiu Wei Bi has been identified as the actual controller of the company after the acquisition [1]

开源证券股份有限公司 关于江苏四环生物股份有限公司 详式权益变动报告书 声明 开源证券股份有限公司(以下简称"开源证券"或"本财务顾问")接受碧水 农业投资的委托，担任碧水农业投资本次权益变动的财务顾问。2025年1月23日， 上市公司公告了《江苏四环生物股份有限公司详式权益变动报告书》。根据《上 市公司收购管理办法》，本财务顾问持续督导期为2025年1月23日至收购完成后12 个月。 四环生物于2025年10月25日披露了《2025年三季度报告》。通过日常沟通并 结合上市公司2025年三季度报告、其他定期公告和临时公告，本财务顾问出具本 持续督导期的持续督导意见。 作为本次权益变动的财务顾问,开源证券出具的持续督导意见是在假设本次 权益变动的各方当事人均按照相关协议条款和承诺全面行其所有职责的基础上提 出的。本财务顾问特作如下声明： (一)本意见所依据的文件、资料及其他相关材料基于的假设前提是上述资料 和意见真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏；本财务顾 问未对上述资料和意见作出任何承诺或保证。 之 2025年第三季度持续督导意见 财务顾问 二零二五年十一月 (二)本意见不构成对四环生物的 ...

Core Viewpoint - The company, Jiangsu Sihuan Biological Co., Ltd., has released its third-quarter financial report for 2025, ensuring the accuracy and completeness of the information disclosed [1][2]. Financial Data - The third-quarter financial report has not been audited [8]. - The company does not require retrospective adjustments or restatements of previous accounting data [3]. - There are no non-recurring profit and loss items applicable for the reporting period [3]. Shareholder Information - The company has provided details regarding the total number of shareholders and the shareholding status of the top ten shareholders [4][5]. Strategic Cooperation - Jiangsu Chenwei Ecological Park Technology Co., Ltd. has signed a strategic cooperation agreement with Jiangyin Xinguangfa Trading Co., Ltd. to provide a stable supply of seedlings, with a total contract value of 26,098,107 yuan [5]. Governance and Compliance - The company is in the process of formulating and revising several governance systems to enhance operational standards, in accordance with relevant laws and regulations [9][11]. - The board of directors has approved the third-quarter report and various governance proposals, all receiving unanimous support [12][14].